T2684
TiterMax® Gold Adjuvant
liquid
Synonyme(s) :
TiterMax adjuvant
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderGeneral description
TiterMax Gold Adjuvant contains three essential ingredients: a new block copolymer, CRL-8300, squalene (a metabolizable oil) and a sorbitan monooleate.
Application
TiterMax® Gold Adjuvant has been used:
- to emulsify soluble antigen-1 (Ag-1) to immunize animals to generate fully human monoclonal antibodies from XenoMouse strains
- to inject GST-dGIPC (Drosophila homolog of GAIP interacting protein) protein into rats for generating antibodies against dGIPC protein
- with Drosophila CtBP (dCtBP) protein in phosphate-buffered saline (PBS) to subcutaneously inject in a New Zealand female rabbit
Biochem/physiol Actions
Specific proteins can be emulsified with equal volume of TiterMax® Gold Adjuvant to immunize lab animals and extract antibodies from them.
TiterMax Gold is a new and improved water-in-oil adjuvant. By developing a new block copolymer and eliminating the silica from the formulation, TiterMax Gold appears to be less toxic and more effective than TiterMax Classic. The optimum volume of TiterMax Gold for an emulsion is twice that of TiterMax Classic.
Legal Information
TiterMax is a registered trademark of TiterMax USA, Inc
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Classe de stockage
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Seppo Parkkila et al.
BMC clinical pathology, 8, 2-2 (2008-02-20)
S100P is a Ca2+ binding protein overexpressed in a variety of cancers, and thus, has been considered a potential tumor biomarker. Very little has been studied about its normal expression and functions. We examined S100P expression in normal human tissues
Jihyun Kim et al.
Biochemical and biophysical research communications, 402(3), 565-570 (2010-10-30)
To identify genes that function in the adult neural system, we screened pools of P element-mediated mutants and tested locomotor activity of homozygous flies. Of 1014 P element-mutagenized lines, 638 were homozygous viable. These lines were tested for climbing ability
Fernando Garces et al.
Cell reports, 30(6), 1714-1723 (2020-02-13)
Calcitonin-gene-related peptide (CGRP) plays a key role in migraine pathophysiology. Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine.
Andrew W Drake et al.
Analytical biochemistry, 328(1), 35-43 (2004-04-15)
Two biophysical methods, Biacore and KinExA, were used to kinetically and thermodynamically characterize high-affinity antigen/antibody complexes. Three to five independent experiments were performed on each platform with three different antigen/antibody complexes possessing nanomolar to picomolar equilibrium dissociation constants. By monitoring
Ning Shen et al.
International journal of molecular sciences, 20(9) (2019-05-15)
Alpha-synuclein is considered the major pathological protein associated with Parkinson's disease, but there is still no effective immunotherapy which targets alpha-synuclein. In order to create a safer and more effective therapy against PD, we are targeting an epitope of alpha-synuclein
Contenu apparenté
Instructions
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique